Toxicogenomics and drug discovery: will new technologies help us produce better drugs? (pdf)
Nature Reviews Drug Discovery 1, 84-88 (2002)

(Note: Current Rosetta Inpharmatics employees are shown in boldface type.)

Roger Ulrich¹, Stephen H. Friend¹.

Abstract

Acting on reports in the late 1980s that most drug candidates fail in development, pharmaceutical discovery programmes responded by devising ways to increase the number of chemicals in the pipeline. With discovery now driven primarily by chemistry and high-throughput screening, the biological effects and, in particular, the toxicity of new compounds are largely not appreciated until a compound enters development. Arguably, this paradigm has produced more failures rather than delivering more successes--with more chemicals to examine, much less is known about any single agent before costly development studies are initiated. The emerging field of toxicogenomics is enabling us to ask detailed questions about drug effects very early on, thereby fundamentally changing our approach to drug discovery.

To view other supplementary materials, please visit http://www.nature.com/nrd/ (opens new window).

¹Rosetta Inpharmatics
12040 115th Avenue NE
Kirkland, Washington 98034, USA.
roger_ulrich@merck.com